Current stock page

Financial Data

BBNX Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareMedical - DevicesScore data as of Nov 18, 2026

BBNXBeta Bionics, Inc.

Healthcare / Medical - Devices

Low Priority

In Line With Peers

NeutralEdge 5/10
$14.33−$0.39 (−2.65%)

Latest quote

  • Momentum
    72
  • Value
    39
  • Quality
    53
  • Risk resilience
    36
  • Sentiment
    —
algovestiq.comScore data as of Nov 18, 2026

Latest Quarter at a Glance

Quarter ended Sep 30, 2026, compared with the same quarter a year earlier.

Revenue
$35.51M
+30.3% YoY
Net income
-$24.35M
−71.4% YoY
Free cash flow
-$14.56M
−45.5% YoY
Operating margin
-74.9%
−12.4 pts YoY

Quarterly Financial Statements

Updated Nov 19, 2026.

BBNX, last 8 quarters. YoY compares the latest quarter with the same quarter a year earlier.

Income statement
Income statement, last 8 quarters, newest first
MetricTrendYoYSep '26Jun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24
Revenue+30.3%$36M$32M$28M$32M$27M$23M$18M$20M
Gross profit+34.5%$20M$19M$16M$19M$15M$13M$9M$12M
Operating income−56.1%−$27M−$26M−$24M−$16M−$17M−$20M−$19M−$13M
Net income−71.4%−$24M−$23M−$22M−$13M−$14M−$17M−$29M−$18M
EPS (diluted)−57.6%−$0.52−$0.53−$0.49−$0.33−$0.33−$0.39−$0.66−$0.42
Gross margin+1.8 pts57.3%59.0%59.5%59.0%55.5%53.8%50.9%57.2%
Operating margin−12.4 pts-74.9%-79.9%-87.9%-50.2%-62.5%-85.5%-105.7%-63.8%
Net margin−16.5 pts-68.6%-73.1%-79.3%-41.9%-52.1%-72.6%-162.5%-88.6%
Cash flow
Cash flow, last 8 quarters, newest first
MetricTrendYoYSep '26Jun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24
Operating cash flow−40.8%−$12M−$15M−$24M−$9M−$9M−$14M−$20M−$14M
Capital expenditure−77.5%−$2M−$1M−$1M−$2M−$1M−$2M−$333K−$561K
Free cash flow−45.5%−$15M−$16M−$25M−$11M−$10M−$15M−$20M−$15M
Free cash flow margin−4.3 pts-41.0%-48.9%-91.3%-32.8%-36.7%-66.2%-115.1%-72.6%
Balance sheet
Balance sheet, last 8 quarters, newest first
MetricTrendYoYSep '26Jun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24
Total assets+34.5%$444M$292M$304M$329M$330M$330M$338M$150M
Total liabilities+20.1%$42M$36M$33M$41M$35M$28M$24M$74M
Shareholders' equity+36.2%$401M$256M$271M$288M$295M$302M$314M$76M
Total debt−20.6%$6M$7M$7M$7M$8M$7M$7M$7M
Cash and equivalents+111.9%$82M$44M$30M$32M$38M$35M$42M$30M
Valuation and ratios
Valuation and ratios, last 8 quarters, newest first
MetricTrendYoYSep '26Jun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24
P/B ratio−1.112.482.642.011.893.59———
Return on equity+5.7 pts-20.7%-28.5%-24.5%-25.5%-26.4%-24.3%-22.6%-72.0%
Debt to equity−0.010.020.030.030.030.030.020.020.10
Free cash flow yield−0.9 pts-6.6%-9.1%-11.2%-10.4%-5.7%———

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
P/E ratio-7.87x
P/B ratio1.71x
Revenue growth (YoY)30.28%
EPS growth (YoY)-57.58%
Gross margin58.63%
Operating margin-72.75%
ROE-27.33%
ROIC-22.45%
Debt to equity0.02
FCF yield-9.96%

As of Nov 18, 2026

Technical indicators
MetricValue
Close
As of Nov 18, 2026
$14.33
Volume
As of Nov 13, 2026
1.1M
RSI (14)
As of Nov 13, 2026
45.53
MACD
As of Nov 13, 2026
-0.55
MACD signal
As of Nov 13, 2026
-0.55
MACD histogram
As of Nov 13, 2026
0
ADX (14)
As of Nov 13, 2026
13.02
SMA (50)
As of Nov 13, 2026
$18.47
SMA (200)
As of Nov 13, 2026
$14.82
ATR (14)
As of Nov 13, 2026
$1.49
Historical volatility (annualized)
As of Nov 13, 2026
109.57%
Volume (20-day average)
As of Nov 13, 2026
1.19M
Risk measures
MetricValue
Resilience score36/100
Beta1.47
Annual volatility84.66%
Max drawdown-72.30%
Sharpe ratio-0.16
VaR (95%, 1-day)-7.37%

As of Nov 18, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

BBNX Financial Data FAQ

What is Beta Bionics, Inc.'s revenue?

Beta Bionics, Inc.'s revenue is one of the core financial data points for BBNX. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Beta Bionics, Inc.'s revenue growing?

Revenue growth shows whether Beta Bionics, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is BBNX's EPS?

BBNX's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Beta Bionics, Inc.'s net income?

Beta Bionics, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Beta Bionics, Inc. generate?

Free cash flow shows how much cash Beta Bionics, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Beta Bionics, Inc. have?

Cash and debt help frame BBNX's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.